Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAC-2: ARV-471 versus fulvestrant in ER-positive/HER2-negative advanced breast cancer after progression on endocrine-based therapy
CTR20230846Phase 3Active
- Sponsor
- Pfizer
- Start
- Jul 2023
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vepdegestrant, fulvestrant in breast cancer, sponsored by Pfizer. Started Jul 2023; status: active.
02
Drugs
vepdegestrantfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20230846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230846.